Sanyou Bio

Sanyou Bio offers research reagents that go beyond standard RUO offerings. Their antibodies are engineered for robust bioactivity and come with control antibodies to support accurate benchmarking and experimental validation. Each batch undergoes pharmaceutical-grade quality control, including Size Exclusion Chromatography (SEC), to verify product integrity and high monomer purity—ensuring consistency and reproducibility in every experiment. Whether you’re screening, validating, or optimizing, Sanyou provides the high-quality data and dependable tools needed to make confident, data-driven decisions. Trust in Sanyou reagents for unmatched quality, validation, and value.

Unique Selling Points (USP’s)

Sanyou Bio specializes in recombinant RUO reference antibodies for drug discovery. Their most popular offerings include:

• Monoclonal antibodies: Targeting key oncology and immunological markers.
• Bispecific antibodies: Include PD1-based formats.
• Antibody-drug conjugates (ADC).

All antibodies are lyophilized to ensure stability, preservative-free, and convenient for shipping and storage.

Key selling points for Sanyou Bio’s catalog products are:

• High Quality: >95% purity, <1EU/mg endotoxin, preservative-free, suitable for in vitro and in vivo applications.
• Ready to use: Lyophilized, off-the-shelf products, available for immediate shipment.
• Robust validation: Transparent Certificates of Analysis (COAs) with binding activity data.
• Applications: Suitable for ELISA, flow cytometry, and functional assays.
• Benchmark (reference) Abs: Reference antibodies for accurate experimental validation.

Sanyou Bio’s Contributions:

• Atezolizumab (CHA083): A humanized anti-PD-L1 antibody used in mouse models to assess resistance mechanisms in tumor immunotherapy.
• Control Antibodies:
  • Isotype IgG1 (CHA401)
  • Human IgG4 control (COA001)

These products ensured proper experimental controls for immunotherapy intervention analysis.

Bio-Connect supplies their products in the Benelux. If you have any questions, please contact us.